Bryan Geoffrey Morton

Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom.

Aircraft Medical Ltd. develops and produces medical devices that focus on the needs of anesthesia and critical care professionals. It offers video scope, video laryngoscope, medical device, laryngoscope, difficult intubation, camera stick, airway management and difficult airway management. The company was founded by Matthew John Ross McGrath in June 2001 and is headquartered in Edinburgh, the United Kingdom.

Dechra Pharmaceuticals Ltd. is a holding company, which engages in the veterinary pharmaceuticals and related products business. It operates through the following segments: European Pharmaceuticals; North American Pharmaceuticals; and Pharmaceuticals Research and Development. The European Pharmaceuticals segment markets and sells licensed pharmaceuticals and specialist pet foods to the veterinary profession in Europe. The North American Pharmaceuticals segment focuses on the sale of a range of endocrine, ophthalmic, dermatological, and equine products in North America. The Pharmaceuticals Research and Development segment develops and licenses Dechra's own branded veterinary product portfolio of novel and generic pharmaceuticals and specialist pet diets. The company was founded in 1819 and is headquartered in Northwich, the United Kingdom.